Jiangsu Hansoh Pharmaceutical Co., Ltd.
Clinical trials sponsored by Jiangsu Hansoh Pharmaceutical Co., Ltd., explained in plain language.
A Chinese pharmaceutical company focused on oncology, CNS, and metabolic diseases.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- Can a common antibiotic change how an experimental drug works? Results expected Sep 2026 (estimated)
- Radioactive tracer reveals the Body's journey of an experimental drug Results expected Sep 2026 (estimated)
- Lung cancer drug interaction study aims to uncover safe dosing Results expected Nov 2026 (estimated)
- New drug HS-20136-2 enters first human safety trial Results expected Dec 2026 (estimated)
- New lung cancer pill targets resistant mutations in early trial Results expected Dec 2026 (estimated)
-
New Weight-Loss drug shows promise in large trial
Disease control CompletedThis study tested a new medicine called HS-20094 to help overweight and obese adults lose weight. About 600 people took either the drug or a placebo for up to 48 weeks. The main goals were to see how much weight they lost and how many lost at least 5% of their starting weight.
Phase 3 • Sponsor: Jiangsu Hansoh Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 13:04 UTC
-
New Weight-Loss shot shows promise in early trial
Disease control CompletedThis Phase 2 study tested an investigational drug called HS-20094 in 200 overweight or obese adults. Participants received either the drug or a placebo injection over several weeks. The main goal was to see how much weight they lost and whether the drug was safe.
Phase 2 • Sponsor: Jiangsu Hansoh Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 13:02 UTC
-
New schizophrenia drug shows promise in reducing symptoms
Symptom relief CompletedThis study tested a new medication called HS-10380 in 363 Chinese adults hospitalized with acute schizophrenia. The goal was to see if it reduces symptoms like hallucinations and delusions better than a placebo or an existing drug. Participants took the drug for 6 weeks, and doct…
Phase 2 • Sponsor: Jiangsu Hansoh Pharmaceutical Co., Ltd. • Aim: Symptom relief
Last updated Jun 27, 2026 12:23 UTC